Exagen (Exagen) Buyback Yield % : 0.00 (As of Jun. 08, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Exagen Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Exagen's current buyback yield was 0.00%.

Exagen Buyback Yield % Historical Data

The historical data trend for Exagen's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exagen Buyback Yield % Chart

Exagen Annual Data

Trend

Dec13

Dec14

Dec15

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buyback Yield %

Get a 7-Day Free Trial

-15.81

-36.78

Exagen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Buyback Yield %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Exagen's Buyback Yield %

For the Diagnostics & Research subindustry, Exagen's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exagen's Buyback Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exagen's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Exagen's Buyback Yield % falls into.

Exagen Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Exagen's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	0)	/	33.921341
	=	0.00%

Exagen's annualized Buyback Yield for the quarter that ended in Mar. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	4	/	27.535461
	=	0.00%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2024) data.

Exagen Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Exagen's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Exagen (Exagen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (NAS:XGN) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

E08A:Germany

Address

1261 Liberty Way, Vista, CA, USA, 92081

Website

https://www.exagen.com

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Executives

John Aballi	director, officer: President and CEO	C/O DECIPHER BIOSCIENCES, INC., 6925 LUSK BLVD, SUITE 200, SAN DIEGO CA 92121
Paul Kim	director	4399 SANTA ANITA AVE, EL MONTE CA 91731
Tullis Growth Fund Ii, L.p.	10 percent owner	11770 US HWY 1, STE 503, PALM BEACH GARDENS FL 33408
Kamal Adawi	officer: Chief Financial Officer	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92131
Mark Hazeltine	officer: Chief Operating Officer	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Wendy S. Johnson	director	800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
Tullis James L L	director, 10 percent owner	100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Ana Hooker	director	441 CHARMANY DRIVE, MADISON WI 53719
Frank Stokes	director	C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Hunt Holdings Limited Partnership	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Nmsic Co-investment Fund, L.p.	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Debra Zack	officer: Chief Medical Officer	C/O EXAGEN, INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
H.i.g. Bio-exagen, L.p.	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Thierry Dervieux	officer: Chief Scientific Officer	C/O EXAGEN DIAGNOSTICS, INC., 1261 LIBERTY WAY, VISTA CA 92081
Nmsic Focused Llc	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081